Literature DB >> 1701292

Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations.

G A Ricaurte1, K T Finnegan, I Irwin, J W Langston.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1701292     DOI： 10.1111/j.1749-6632.1990.tb16919.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  21 in total

1.  Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.

Authors:  H R Sumnall; L Jerome; R Doblin; M C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

2.  Neurotoxicity of methamphetamine and methylenedioxymethamphetamine.

Authors:  L S Seiden; R Lew; J E Malberg
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

Review 3.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

4.  Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (Ecstasy) users: preliminary results.

Authors:  Liesbeth Reneman; Charles B L M Majoie; Herman Flick; Gerard J den Heeten
Journal:  AJNR Am J Neuroradiol       Date:  2002-02       Impact factor: 3.825

5.  In vitro neuronal and vascular responses to 5-HT in rats chronically exposed to MDMA.

Authors:  D M Cannon; A K Keenan; P J Guiry; C Buon; A W Baird; G J McBean
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 6.  Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').

Authors:  U D McCann; S O Slate; G A Ricaurte
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 7.  Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.

Authors:  G Huether; D Zhou; E Rüther
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

8.  Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.

Authors:  G A Ricaurte; U D McCann
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

9.  Effects of acute 3,4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: a preliminary study.

Authors:  Surilla Randall; Chris-Ellyn Johanson; Manuel Tancer; Timothy Roehrs
Journal:  Sleep       Date:  2009-11       Impact factor: 5.849

10.  Memory-related hippocampal functioning in ecstasy and amphetamine users: a prospective fMRI study.

Authors:  Benjamin Becker; Daniel Wagner; Philip Koester; Katja Bender; Christoph Kabbasch; Euphrosyne Gouzoulis-Mayfrank; Jörg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2012-09-23       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.